Alumis Inc. (ALMS)
NASDAQ:ALMS
Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$24.99
-$0.47(-5.84%)
At close: 4:00 PM EST
$24.99
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.59M
Market Cap
$2.75B
Enterprise Value$2.64B
Total Cash (Recent Filing)$522.94M
Total Debt (Recent Filing)$35.66M
Price to Earnings (P/E)―
Beta-1.48
Next Earnings
Aug 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding123,432,076
10 Day Avg. Volume2,295,855
30 Day Avg. Volume1,592,686
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue313.96
Enterprise Value/Gross Profit350.27
Enterprise Value/Ebitda-6.17
Forecast
1Y Price Target
$40.67Price Target Upside62.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$8.12M
Bulls Say, Bears Say
Bulls Say
Phase 3 Efficacy And SafetyRobust Phase 3 results with high PASI90/PASI100 rates and a favorable safety profile underpin a structural shift from development-stage uncertainty toward regulatory submission and potential commercialization. This outcome materially strengthens competitive positioning for an oral TYK2 therapy and supports partnership or licensing optionality over the medium term.
Low Financial LeverageVery low debt relative to equity provides durable financial flexibility to fund ongoing clinical programs, pursue regulatory filing activities, and negotiate strategic partnerships without immediate insolvency risk. A strengthened balance sheet reduces refinancing pressure and preserves optionality across 2-6 months as clinical milestones unfold.
High Gross Margins (unit Economics)Elevated gross margins indicate attractive unit economics for eventual commercialization, suggesting product-level profitability potential once fixed R&D and SG&A are scaled or offset. This structural efficiency can lead to strong long-term margins post-approval, improving returns if revenue ramps as projected.
Bears Say
Large Cash BurnSustained, material negative operating and free cash flow creates a structural funding requirement, forcing reliance on equity or debt raises or partnership deals. Persistent cash burn risks diluting shareholders, shortening runway, and constraining the company's ability to independently complete pivotal programs absent external financing.
Weak And Shrinking Revenue BaseA very small, declining revenue base means the company lacks commercial cash inflows to offset development costs, leaving operations dependent on financing and milestone events. This structural revenue weakness increases execution risk and heightens sensitivity to trial timelines and regulatory outcomes over the next several quarters.
Large Operating Losses And Negative ROEDeep operating losses and materially negative returns on equity indicate that current operations are destroying shareholder value. If losses persist, equity could be eroded and strategic options narrowed, necessitating dilutive financing or asset sales and raising long-term sustainability concerns absent imminent revenue generation.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $2.75B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 79 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on May 14, 2026. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.003.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.72.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,432,076 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -7.146%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (62.73% Upside)
$40.67 (62.73% Upside)
Hedge Fund Trend
Increased
By 294.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.50%
12-Months-Change
Fundamentals
Return on Equity
-54.63%
Trailing 12-Months
Asset Growth
157.02%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$40.67
▲(62.73% Upside)
Technical Analysis
Ownership Overview
56.33% Insiders
5.30% Mutual Funds
3.31% Other Institutional Investors
26.92% Public Companies and Individual Investors